Esperion Therapeutics (ESPR) to Buy at Jefferies ahead of ACC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Morgan Stanley Opens Catalyst Driven Idea on Esperion Therapeutics (ESPR)
February 27, 2023 4:21 PM ESTMorgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $9.00 price target on Esperion Therapeutics (NASDAQ: ESPR)
The analyst comments "What is the catalyst? Data from Esperion's CLEAR outcomes study for LDLlowering drug Nexletol (bempedoic acid) in 14,000+ statin intolerant patients at high risk for cardiovascular disease will be presented in a... More
Jefferies Assumes, Upgrades Esperion Therapeutics (ESPR) to Buy; Sees 100% Upside
February 24, 2023 6:49 AM EST(Updated - February 24, 2023 9:20 AM EST)
Jefferies analyst Dennis Ding assumes coverage on Esperion Therapeutics (NASDAQ: ESPR) and upgraded shares to Buy with a price target of $12 (from $6).
The analyst commented, "Assuming and UG to Buy on better mgmt tone... More
